Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters








Database
Language
Publication year range
1.
Opt Lett ; 44(2): 339-342, 2019 Jan 15.
Article in English | MEDLINE | ID: mdl-30644895

ABSTRACT

The enhancement of bovine serum albumin (BSA) fluorescence detection using a hierarchical laser-induced periodic surface structure (LIPSS) at the TC4 titanium alloy substrate was experimentally demonstrated. The hierarchical structure, including microgrooves, submicrometer LIPSS, and nanoparticles, has been achieved by a femtosecond laser. Due to the surface plasmon polariton induced by the LIPSS and localized surface plasmon resonance induced by nanoparticles, the enhancement factor of BSA fluorescence detection reached 74. Further, a good linear relationship between the concentration of copper ion inside and BSA fluorescence intensity was found in the range between 5 and 35 µg/mL. Our method explores a simple, reproducible, and pollution-free technique for surface-enhanced fluorescence.

2.
J Huazhong Univ Sci Technolog Med Sci ; 31(1): 58-61, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21336724

ABSTRACT

The benefit achieved by concurrent chemoradiotherapy (CCR) and sequential chemoradiotherapy (SCR) vs radiotherapy (RT) alone for patients with stage II-IVa nasopharyngeal carcinoma (NPC) was compared. A total of 113 patients with stage II-IV a NPC were allotted into CCR group (n=38), SCR group (n=36) and RT alone group (n=39). All patients were irradiated with the same RT technique to ≥66 Gy at 2 Gy per fraction, conventional 5 fractions/week in all groups. The CCR group received concurrent chemotherapy of weekly cisplatin for 7 weeks, and the SCR group received neoadjuvant and (or) adjuvant chemotherapy. The results showed that the 3- and 5-year overall survival rate was significantly higher in CCR group than in RT alone group (92.16% vs 61.54%, 81.58% vs 51.28%, P<0.005). The median survival time was significantly longer in CCR group than in RT alone group (67.8 months vs 52.7 months, P<0.005). It was concluded that CCR could significantly improve overall survival rate, progression-free survival rate, and median survival time when compared with RT alone.


Subject(s)
Chemoradiotherapy/methods , Nasopharyngeal Neoplasms/therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols , Cisplatin/administration & dosage , Disease-Free Survival , Female , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/pathology , Neoplasm Staging , Prospective Studies , Survival Analysis , Young Adult
3.
J Huazhong Univ Sci Technolog Med Sci ; 31(1): 62-66, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21336725

ABSTRACT

The inhibitory effects of Endostar in combination with radiotherapy in BALB/c nude mice model of human CNE2 nasopharyngeal carcinoma and the mechanism were investigated. In nude mice model of CNE2 nasopharyngeal carcinoma, the inhibitory rate and the sensitizing enhancement ratio (E/O) were calculated according to the tumor volumes in different groups. The expression of microvascular density (MVD) in tumor tissues was examined by using immunohistochemistry staining. The transcription of VEGF gene was detected by using RT-PCR. The inhibitory rate in Endostar+ radiotherapy group was higher than in other groups. In Endostar+radiotherapy group, the tumor volume was significantly decreased and the E/O ratio was 2.335, suggesting that Endostar could be a radiosensitizer. The expression of MVD of tumor tissues in Endostar+radiotherapy group was reduced significantly. The expression of the MVD in treatment groups was significantly different from that in control group (P<0.05). Compared to other groups, VEGF mRNA expression in Endostar+radiotherapy group was decreased remarkably. Endostar in combination with radiotherapy significantly inhibited the growth of CNE2 tumor. The combination therapy decreased the expression of VEGF, and inhibited tumor angiogenesis and proliferation. When combined with radiotherapy, Endostar acted as a radiosensitizer.


Subject(s)
Endostatins/therapeutic use , Nasopharyngeal Neoplasms/therapy , Radiation-Sensitizing Agents/therapeutic use , Radiotherapy , Animals , Cell Line, Tumor , Combined Modality Therapy , Female , Mice , Mice, Inbred BALB C , Mice, Nude , Nasopharyngeal Neoplasms/pathology , Neoplasm Transplantation , Neovascularization, Pathologic/prevention & control , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Proteins/therapeutic use , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL